Tonix Pharmaceuticals' TNX-1700 Shows Promise in Enhancing Immunotherapy for Gastric Cancer

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) has published preclinical data in Cancer Cells demonstrating that its fusion protein candidate, mTNX-1700, significantly improves survival rates and reduces metastases in mouse models of gastric cancer. This development, achieved in collaboration with Columbia University Medical School, highlights mTNX-1700's ability to enhance the effectiveness of anti-PD-1 immunotherapy by depleting immunosuppressive neutrophils and inhibiting cancer-driven granulopoiesis. The human counterpart, TNX-1700, is currently under development for treating gastric and colorectal cancers, with CEO Dr. Seth Lederman emphasizing its potential to address checkpoint resistance in solid tumors.

The findings underscore the importance of TNX-1700 in the ongoing search for more effective cancer treatments, particularly for patients who do not respond to current immunotherapy options. By targeting specific immune suppression mechanisms, TNX-1700 could represent a significant advancement in the field of oncology, offering hope for improved outcomes in difficult-to-treat cancers. For more details on the study, visit https://ibn.fm/PPxKC.